2L
GNMX

22NW LP’s Aevi Genomic Medicine Inc GNMX Stock Holding History

22NW LP’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-155,000
Closed -$195K – 83
2017
Q3 		$195K Hold
155,000
– – 0.11% 84
2017
Q2 		$206K Hold
155,000
– – 0.12% 78
2017
Q1 		$288K Buy
+155,000
New +$701K 0.17% 86

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

22NW LP's GNMX Position: Q4 2017 in Review

22NW LP sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 155,000 shares — an estimated $195K sold.

22NW LP first reported a position in GNMX in Q1 2017 and held it in 3 quarters. The position peaked at $288K in Q1 2017. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • 22NW LP reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • 22NW LP sold 155,000 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $195K.
  • 22NW LP first reported a position in Aevi Genomic Medicine Inc in Q1 2017 and held it in 3 quarters.
  • 22NW LP's Aevi Genomic Medicine Inc position peaked at $288K in Q1 2017.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on 22NW LP's 13F filing for Q4 2017, filed 14 Feb 2018.